Trulicity (dulaglutide) is a GLP-1 receptor agonist that does cause weight loss, but it is not approved by the FDA for weight management in people without diabetes. It is approved only for type 2 diabetes and cardiovascular risk reduction. Doctors sometimes prescribe it off-label for weight loss, yet the evidence base for using dulaglutide specifically in non-diabetic populations is thin compared to alternatives like semaglutide (Wegovy) or tirzepatide (Zepbound), which have dedicated weight-loss approvals and produce substantially more weight loss in clinical trials.
How Trulicity Causes Weight Loss
Dulaglutide belongs to the GLP-1 receptor agonist class, a group of injectable medications that mimic a gut hormone called GLP-1. The weight-loss effects come from multiple pathways working at the same time. In the brain, the drug activates receptors in areas that regulate appetite, boosting signals that promote fullness while dialing down signals that drive hunger and food-seeking behavior. In the gut, it slows the rate at which your stomach empties after a meal, which means you feel satisfied longer and tend to eat less at each sitting.1The American Journal of Medicine. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation
Beyond appetite, there is growing evidence that GLP-1 receptor agonists change how the brain processes reward. Clinical studies show these drugs alter neural responses to food-related cues, which may help explain why people on them report not just eating less but genuinely wanting food less.2PubMed Central. GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory This is different from the willpower-based approach most diets rely on. The medication shifts the biological set point for hunger rather than asking you to override it.
What the Evidence Actually Shows in People Without Diabetes
Here is where Trulicity’s story gets complicated. While the GLP-1 receptor agonist class as a whole has been extensively studied for weight loss in non-diabetic adults, most of those trials tested other drugs in the class, not dulaglutide. A 2024 systematic review of 26 randomized controlled trials involving over 15,000 non-diabetic participants found that the commercially available agents with weight-loss data were liraglutide, semaglutide, and tirzepatide. Dulaglutide was not among the three commercially available drugs highlighted, and the review did not report dedicated non-diabetic weight-loss figures for it.3Annals of Internal Medicine. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
The weight-loss data we do have for dulaglutide comes largely from diabetes trials, where it was tested at doses of 1.5 mg, 3.0 mg, and 4.5 mg per week. In one exploratory analysis of the AWARD-11 trial, patients with type 2 diabetes lost an average of about 3 kg on the 1.5 mg dose, 4 kg on the 3.0 mg dose, and nearly 5 kg on the 4.5 mg dose over 36 weeks.4PubMed Central. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11 That is meaningful but modest, especially compared to what newer drugs achieve.
One piece of good news for non-diabetic users: a meta-analysis found that people without diabetes tend to lose more weight on GLP-1 agonists than people with diabetes, by roughly 2.5 kg on average.5Obesity Medicine. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis So the diabetes-trial numbers for dulaglutide may understate what a non-diabetic person would experience. But even with that bump, the weight loss is still well below what semaglutide or tirzepatide deliver.
How Trulicity Stacks Up Against Competitors
The comparison is not favorable for Trulicity. In that same systematic review of non-diabetic adults, semaglutide at 2.4 mg weekly (the Wegovy dose) produced up to about 14% body weight loss after 68 weeks, and tirzepatide at 15 mg weekly delivered up to roughly 18% loss after 72 weeks. Even the older drug liraglutide, at its weight-loss dose, produced about 6% loss in 26 weeks.6Annals of Internal Medicine. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes Meanwhile, dulaglutide at its highest approved dose in diabetes trials produced about 5 kg of loss, which for a typical participant translates to around 5% of body weight.
A head-to-head indirect comparison confirmed the gap. Even at its standard diabetes dose of 1.0 mg, semaglutide outperformed dulaglutide at higher doses of 3.0 and 4.5 mg for weight reduction, with estimated differences of about 2.7 kg and 2.0 kg respectively.7PubMed Central. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg In other words, a lower dose of the competitor beat a higher dose of Trulicity. A modeling study of patients switching from semaglutide to dulaglutide found that some additional weight loss continued after the switch, but the overall trajectory was less impressive than staying on semaglutide at higher doses would have been.8PubMed Central. A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide
This gap matters for someone without diabetes whose primary goal is weight loss. The FDA has approved specific formulations of semaglutide and tirzepatide for chronic weight management in non-diabetic adults. No such approval exists for dulaglutide. The drug was designed and tested primarily as a glucose-lowering agent, and its weight-loss effects, while real, are essentially a secondary benefit rather than the main event.
What Happens to Body Composition
A concern with any weight-loss medication is how much of the lost weight comes from fat versus muscle. A study tracking body composition changes after three months of dulaglutide found that body weight, body fat, and visceral fat area all decreased, but so did lean body mass and skeletal muscle mass. The silver lining was that the proportion of lean mass actually went up relative to total body weight, meaning the drug preferentially reduced fat, but muscle loss was still present.9Diabetes, Metabolic Syndrome and Obesity. Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
This pattern is common across GLP-1 agonists and is not unique to dulaglutide. If you are considering any drug in this class, adding resistance exercise during treatment is a practical way to protect muscle mass. The body composition concern is worth being aware of, but it is not a reason to avoid one GLP-1 agonist in favor of another, since they all share this tendency.
Side Effects You Should Expect
Gastrointestinal problems are the most common issue with Trulicity, and many people experience them, especially in the first few weeks. In clinical trials, nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, and fatigue were each reported by at least 5% of patients.10PubMed Central. Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist For many people these symptoms are worst during dose escalation and improve over time, but for some they persist enough to lead to discontinuation.
More serious risks exist, though they are uncommon. Pancreatitis has been reported at a rate of about 1.4 cases per 1,000 patient-years with dulaglutide, compared to about 0.9 per 1,000 patient-years in control groups.11PubMed Central. Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report The difference is small in absolute terms, but persistent severe abdominal pain while taking Trulicity warrants immediate medical attention.
Gallbladder problems are another concern. A meta-analysis of randomized trials found that dulaglutide was associated with about a 35% increased risk of gallbladder or biliary diseases compared to placebo.12JAMA Internal Medicine. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases One documented case involved a patient developing acute cholecystitis after 16 months of treatment, ultimately requiring surgical removal of a gangrenous gallbladder.13PubMed Central. Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy Rapid weight loss itself can trigger gallstone formation regardless of the method, so this risk is partly inherent to the weight-loss process, though GLP-1 agonists appear to add something beyond that baseline risk.
Weight Regain After Stopping
This is arguably the most important issue for anyone considering Trulicity for weight loss, and the data are sobering. When people stop taking GLP-1 receptor agonists, the weight typically comes back. Research estimates that 60% to 90% of the lost weight returns within a year of discontinuation, along with a reversal of improvements in blood pressure, cholesterol, and blood sugar levels.14PubMed. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists Stopping within the first year of treatment appears to carry even higher risks, including increased rates of coronary artery disease and heart failure compared to people who continued therapy.
This means that for sustained weight management, you are likely looking at indefinite use, not a short course. That reality makes the cost, tolerability, and long-term safety profile of the chosen drug much more important. And for a drug that is already less effective for weight loss than its competitors, the prospect of staying on it permanently is harder to justify.
The Adherence Problem
Sticking with any GLP-1 agonist over the long term turns out to be difficult for most people. Dulaglutide adherence has been reported at about 44% over 12 months.15Maaen Journal for Medical Sciences. Patient Adherence to Glucagon Like Peptide-1 Receptor Agonists in Obesity Management: A Narrative Review of Real-World Evidence Among commercially insured non-diabetic adults who started any GLP-1 agonist for obesity, only about a third were still taking their medication at one year. Semaglutide (Ozempic) had the highest one-year persistence rate at about 47%, while liraglutide (Saxenda) had the lowest at about 19%.16PubMed Central. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes
Why do people stop? Side effects play a role, but cost is a major factor. For non-diabetic patients using these drugs off-label, insurance coverage is often denied. Trulicity’s list price runs over $1,000 per month, and without an FDA-approved indication for weight management, you have almost no leverage with your insurer. A health-economic analysis found that dulaglutide was not cost-effective for obesity treatment in the United States, with a cost per quality-adjusted life year far exceeding standard thresholds.17PubMed Central. Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting When the drug is both less effective and equally or more expensive than alternatives that actually have weight-loss approvals, the financial case collapses.
Supply Shortages Affect Everyone
The explosion in demand for GLP-1 agonists has created persistent supply problems. In England, the situation became severe enough that clinicians were told not to start new patients with type 2 diabetes on GLP-1 agonists, and existing patients were warned they might need to switch to insulin if prescriptions could not be filled.18BMJ. Diabetes: Doctors are told not to start new patients on GLP-1 agonists because of shortages Similar shortages have occurred in the United States and other countries.
These shortages disproportionately affect people with diabetes, for whom these medications are medically necessary. Off-label use for weight loss in non-diabetic patients has drawn criticism for contributing to supply constraints, and some healthcare systems have explicitly deprioritized non-diabetic prescriptions during shortage periods. If you are considering Trulicity for weight loss, the possibility that you may face interruptions in supply is worth factoring in, especially given how quickly weight regain begins after stopping.
Why Your Response May Vary
Not everyone loses the same amount of weight on any GLP-1 agonist, and some emerging research is exploring why. Genetic factors appear to play a role. One study examining polygenic influences on weight-loss response found that genetic scores could modify how much weight an individual lost on GLP-1 receptor agonists, though the research is still at an early stage.19Circulation. Abstract 4363148: Polygenic Modification of Weight Loss Response to GLP-1 Receptor Agonists Baseline body mass index and other metabolic factors also influence outcomes, with the AWARD-11 exploratory analysis showing that higher dulaglutide doses produced greater weight loss across different BMI and HbA1c subgroups, but with meaningful individual variation within each group.20PubMed Central. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11
In practical terms, if you are prescribed Trulicity off-label for weight loss, you might lose very little or you might lose a surprising amount. There is no reliable way to predict in advance which category you will fall into. Clinicians typically suggest giving the medication at least 12 to 16 weeks at the target dose before concluding it is not working.
When Trulicity for Weight Loss Could Make Sense
Given everything above, you might wonder why anyone would prescribe Trulicity for weight loss at all. There are a few scenarios where it comes up. If a patient has already tried semaglutide or tirzepatide and could not tolerate the side effects, dulaglutide can be an alternative, since GI side effects vary between drugs in the class even though the overall side-effect profile is similar. Some patients report better tolerability on dulaglutide than on semaglutide, though this is individual and hard to predict.
Insurance quirks can also play a role. Some formularies cover Trulicity but not Wegovy or Zepbound, particularly for patients with prediabetes or other metabolic conditions that sit in a gray zone between clear diabetes and pure obesity. In those cases, a prescriber may choose the drug that the patient can actually access and afford, even if it is not the most effective option on paper.
There is also the matter of cardiovascular benefit. Trulicity has shown reduced cardiovascular events in large trials of people with type 2 diabetes, and for a non-diabetic patient with significant cardiovascular risk factors and obesity, some clinicians may see value in a drug that addresses both weight and heart risk, even if the weight-loss effect is more modest. That said, semaglutide now has cardiovascular outcome data in non-diabetic obese patients as well, so this argument has weakened.
What Trulicity Does to Metabolic Health Beyond Weight
GLP-1 agonists as a class improve several metabolic markers that matter for long-term health, independent of how much weight you lose. These include blood pressure, triglycerides, and inflammatory markers.21PubMed Central. Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review) For a non-diabetic person with obesity, these improvements can matter even if the number on the scale does not change as dramatically as it would on semaglutide. Reduced visceral fat, in particular, is more closely linked to metabolic disease risk than total body weight, and dulaglutide has been shown to reduce visceral fat area specifically.22Diabetes, Metabolic Syndrome and Obesity. Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
The catch is that these metabolic improvements, like the weight loss itself, reverse when you stop the drug. So while the non-scale benefits are real and relevant, they reinforce the same message: you get these benefits only as long as you keep taking the medication. For a drug that is expensive, not approved for this indication, and less effective than alternatives, that indefinite commitment is a steep ask. Most people exploring Trulicity for weight loss would be better served by discussing semaglutide or tirzepatide with their prescriber first, and turning to dulaglutide only if those options are unavailable, unaffordable, or poorly tolerated.